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LETTERS TO THE EDITOR 
Historical Perspective on Noker Monitoring 
JACC’r January I991 Ralorical Milestones ecnon entitled “tbc~ 
torical Vignette Celebrating the 30th Annwersary of Diagnxtic 
Ambulatory Eleclrocardiographic Monitoring and Data Reduction 
Systems.” 
iioring device war conceived exclusively to- idenufy msuffic~ency 
slates lo the end credits indicating that Mrs. N.J. iloanl Halter and 
I collaborated substantially with the author. the artick i* fxfuallr 
faulty. 
For instance. the report of early 1950s dixussionn aith Dr Paul 
Dudley White at the Hoher Research Foundarnn laboratory about 
“attempts to transmit ECG and electroencrphalographc s~gn;dr 
from space back ID earth” is pure fiction: and. more rmportdnt. w 
are Dr. Eliot Corday’s claims of having “worked closely during 
the formative years” of the development of the monaor. 
A couple of pertinent facts. for the record: II the first account uf 
the Holler Research Foundation’s work on 8” ambulatory monitor- 
ing device was published in 1949 la fact tucked away only a~ 
footnote 6). about a decade before Dr. Cordag and Norman Jeffem 
“Jer Holler even became acquainted; 2) Dr Cordag’r first we of 
the monitor did not take p$ce until 1%6?. when 1 pers~nallg 
demonstrated the system--using the same prototype that na being 
released for commerwl pmduction under an already negotiated 
agreement-to him while I was in Los Angeles w related burinear. 
Dr. Corday, along with several other cardiologist\ around Ihe 
country, did participate in cbmcal appliczion of the manufxwed 
waits and subsequentlv Dublished results in the mid IWs. for ahtch 
we were grateful. As for any earber “contributions” he tmarines 
within the convoluted chronology he has canwucted and a~ fir his 
general characterization of Jeff s reliance on him fur crilical adricr 
on the monitor’!, features or future. I hsw an aoalyu\ of Dr. 
Corday’s article detailing several discrepancw that I uauld br 
pleased to share with anyone on rcques~. Also. [he archires ai. rhr 
Montana Historical Society thoroughly documcnr “UT wrk ;I, rhe 
Halter Research Foundation. 
In summary. ceverdl aspect\ of the relerenced January 1991 
Brlick are invalid and I do not recommend it as d reliablr hislonc,d 
auurce on lhe development of the Holtcr moni!vr 
WILFORD R. [“BILL’~) GLASSCOCK 
,UlS Wosdhri~~r 
H&w,. Mwlwa 50601 
ISLS-3 
The prelimmlrj rc~ults of the Third Inlernalional Study of Infarct 
Sun~ral ,iSlS-31 rhowed a h,gher madencc of ,ntracnnial hcmor- 
rhigc in the group treakd Gth duteplase. recombinant ricrue 
plaminugen ,tiliwlor IBurroughc Wellcome‘s rr.PA): 10.75+) com- 
wed n-xh the hueplokinass group: 0.35 <II. 111 contrast. other 
\Iudies. ichich uwd Alteplase (Genentech‘s rl-PAI. such ds “TIMI- 
2” I?) and “GISSI-?” (31. reported a Iowa rdlc uf intracranial 
hemorrhJgc Kl.i? .md 0.455, rcrpectwclyl thdn Ihe n-P.\ arm of fhe 
ISIS.3 clinical Iriill 
pr&xn of the ,tudy. ln the ISIS-3 drvg adm,mr,rat,on prolocol. 
paGents were given one active agent and one p[.xcho. The anis- 
~replaw iAPSACI !w IO be reconstituted and Ihe total contenls 
injected over 3 min Swcpwhinaw was administered as a constant 
unount of 1.5 million U. over I h by mtrweno~s infusion. Only the 
pat~cnls aivcn rt.PA required a weight estmmtion or determination. 
lhrn a weighl.adjuatcd do<e calculation, and formulation of Ihe 
appropnatc in~ri~vcnuub conccnlration to produce a totsI dose ofQ.6 
million Uikg body weight over 4 h 14). 
In none of the official ISIS-3 pre-enrollment data sheets. or the 
follow-up case reporting materials dent ID the dam monitoring 
wmmittcc wcrc tbc Patient5 weights. or the total dose of any ofthe 
apenw actually admi&tered. rep&ted. In this aludy, whichenrolled 
>4h.OnO oatients in 16 coumries. the fornulation of the rt-PA dose 
war the ;nly variable dosing arm. and introduced a source of error 
unique to that group. If the patients’ weights wcrc not accuralely 
dctelmincd. or the rt-PA not mixed correctly (i.e.. solution made up 
85 if the drug were alteplase. and not duteplasel. then patienta could 
have received enough drug for a 95 kg person. the maximal dose 
supplied. 
Wathoul rewcw of the dose administcrcd of a nonstandard drug. 
a dosing error cannot be ruled out as causing the excess of 
intracranial hemorrhage in Ihe rl-PA group,ascompsredloprevious 
studies. ‘Therefore. in all future studier the dose of the medication 
rcccivcd ix ihc test rubiects should be recorded for further analvsls 
and review. 
When the ISIS-? resulls are published it will be possible to discuss 
rhew inlerpretation in delail. In the meantime. il is interestingto note 
that in both LSIS-3 and GISSI.2 (1.2) there appeared to be no 
diffcrcnce at all in S-week mortality between patients allocated 
streptokinase (2,355 death% among 23.691 patients in both wdier 
combined: 9.9%) and Ihose allocated rt.F’A (2.361 death, among 
23.662; 10.0%1. Trsalmcnl with rl-PA was. however. associaled 
with a highly statistically ngmficam excess of stroke “01 just in 
Table 2. Timing of Any Stroke Among Patients Randomized to 
Streptokinase Versus n-PA in ISIS-3 and GISSI-2 (and its 
international extension) 
Day or,flrr:, 
Stroke in liospi~al 
Da) O-l 
GISSI-2 
ISIS-3 
After day I 
GISSI.2 
ISIS-3 
Significance 
Level 
< 0.02 
< 0.002 
D.I 
NS 
Abbrevinlions 81 m Table I 
ISIS-3 but also in GISSI-2 (Table Il. In both studies this excess was 
equivalent to about 4 extra strokes per l.wO patients treated with 
GA and it appeared early aRer the start of treatment (Table 2). 
This excess tiak of strokes WP.S attributed in ISIS-3 ID cerebral 
hemorrhage (39 streptokinase IO.3951 vs. 94 &PA @X7%1; 2p < 
O.MMIl. which is not statislically inconsistent with thenonsignihcant 
excess ofcerebral hemorrhage reported in GISSI-2 (30 streprokinase 
[0.3%] vs. 44 CPA [0.4%]: 2p = 0.1). For mwtaliiy and for stroke. 
therefore. the results from lhese two large (and. hence, statistically 
reliable1 trials are entirely consislent with each other. 
RORY COLLINS. Coordinam 
